Breaking News

Actinium Pharma Selects Medpace

CRO selection marks significant milestone toward start of Iomab-B pivotal trial

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Actinium Pharmaceuticals has selected Medpace as its clinical research organization (CRO) for its pivotal Phase 3 Iomab-B clinical trial. Medpace is a full service CRO that provides Phase 1 – 4 core development services for drug, biologic and device programs. “We worked extremely diligently to identify the right specialist CRO partner for the pivotal Phase 3 Iomab-B clinical trial and we are delighted to announce that we have selected Medpace,” said Felix Garzon, senior vice president, head o...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters